Mott David M

Mott David M is listed in filings as Director at Novavax, Inc.. This profile follows SEC Form 4 activity through Feb 23, 2026, including purchase activity. Recent filings connect the profile to Novavax, Inc. (NVAX), Ardelyx, Inc. (ARDX), and Adaptimmune Therapeutics plc (ADAPY). The current snapshot covers public activity from Jun 14, 2024 to Feb 23, 2026. Reported amounts are shown as $247.9K to $255.5K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.